AN2 Looks To Shift Gears On Phase III Epetraborole Trial On Potentially Lackluster Results
The company said it was pausing enrollment in the Phase III segment of its Phase II/III trial because of efficacy in MAC lung disease.
The company said it was pausing enrollment in the Phase III segment of its Phase II/III trial because of efficacy in MAC lung disease.